Watch highlights from our webinar discussing PDUFA and its impact on rare disease drug development, FDA review timelines, and patient access to therapies. The discussion also covers opportunities for community advocacy during the reauthorization process.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
